Kathryn R Wagner

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Loss of myostatin attenuates severity of muscular dystrophy in mdx mice
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins University, 725 N Wolfe Street, Baltimore, MD 21205, USA
    Ann Neurol 52:832-6. 2002
  2. ncbi Genetic diseases of muscle
    Kathryn R Wagner
    Department of Neurology, Johns Hopkins Hospital, Meyer 5 119, 600 N Wolfe St, Baltimore, MD 21287, USA
    Neurol Clin 20:645-78. 2002
  3. ncbi Approaching a new age in Duchenne muscular dystrophy treatment
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Neurotherapeutics 5:583-91. 2008
  4. ncbi Muscle regeneration in the prolonged absence of myostatin
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 102:2519-24. 2005
  5. ncbi A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 7519, USA
    Ann Neurol 63:561-71. 2008
  6. ncbi Muscle regeneration through myostatin inhibition
    Kathryn R Wagner
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Curr Opin Rheumatol 17:720-4. 2005
  7. ncbi Current treatment of adult Duchenne muscular dystrophy
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins School of Medicine, Meyer 5 119, 600 N Wolfe St, Baltimore, MD 21287, USA
    Biochim Biophys Acta 1772:229-37. 2007
  8. ncbi Myostatin directly regulates skeletal muscle fibrosis
    Zhao Bo Li
    Department of Neurology and Neuroscience, The Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA
    J Biol Chem 283:19371-8. 2008
  9. ncbi Myostatin does not regulate cardiac hypertrophy or fibrosis
    Ronald D Cohn
    McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Neuromuscul Disord 17:290-6. 2007
  10. ncbi Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy
    Saman Nazarian
    Department of Medicine, Johns Hopkins University School of Medicine and the Kennedy Krieger Institute, Baltimore, Maryland 21287, USA
    Pacing Clin Electrophysiol 34:171-6. 2011

Research Grants

  1. Myostatin in Muscle Growth and Regeneration
    Kathryn Wagner; Fiscal Year: 2005

Collaborators

Detail Information

Publications18

  1. ncbi Loss of myostatin attenuates severity of muscular dystrophy in mdx mice
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins University, 725 N Wolfe Street, Baltimore, MD 21205, USA
    Ann Neurol 52:832-6. 2002
    ..Mdx mice lacking myostatin were stronger and more muscular than their mdx counterparts. Diaphragm muscle showed less fibrosis and fatty remodeling, suggesting improved muscle regeneration...
  2. ncbi Genetic diseases of muscle
    Kathryn R Wagner
    Department of Neurology, Johns Hopkins Hospital, Meyer 5 119, 600 N Wolfe St, Baltimore, MD 21287, USA
    Neurol Clin 20:645-78. 2002
    ....
  3. ncbi Approaching a new age in Duchenne muscular dystrophy treatment
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Neurotherapeutics 5:583-91. 2008
    ..However, these challenges are not insurmountable and the next decade will likely see meaningful, new treatment options introduced into the clinical care of patients with Duchenne muscular dystrophy...
  4. ncbi Muscle regeneration in the prolonged absence of myostatin
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 102:2519-24. 2005
    ..Early markers of regeneration are enhanced in the absence of myostatin, suggesting a mechanism for the attenuation of dystrophic features found in mdx mice lacking myostatin...
  5. ncbi A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 7519, USA
    Ann Neurol 63:561-71. 2008
    ..We conducted a safety trial of a neutralizing antibody to myostatin, MYO-029, in adult muscular dystrophies (Becker muscular dystrophy, facioscapulohumeral dystrophy, and limb-girdle muscular dystrophy)...
  6. ncbi Muscle regeneration through myostatin inhibition
    Kathryn R Wagner
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Curr Opin Rheumatol 17:720-4. 2005
    ..An understanding of this potential is relevant because inhibitors of myostatin have recently entered clinical trials...
  7. ncbi Current treatment of adult Duchenne muscular dystrophy
    Kathryn R Wagner
    Department of Neurology, The Johns Hopkins School of Medicine, Meyer 5 119, 600 N Wolfe St, Baltimore, MD 21287, USA
    Biochim Biophys Acta 1772:229-37. 2007
    ..Current and future therapies directed at prolonging the lifespan of those with DMD will result in further increases in this adult population with special needs and concerns. These needs are best addressed in a multidisciplinary clinic...
  8. ncbi Myostatin directly regulates skeletal muscle fibrosis
    Zhao Bo Li
    Department of Neurology and Neuroscience, The Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA
    J Biol Chem 283:19371-8. 2008
    ..These results expand our understanding of the function of myostatin in muscle tissue and provide a potential target for anti-fibrotic therapies...
  9. ncbi Myostatin does not regulate cardiac hypertrophy or fibrosis
    Ronald D Cohn
    McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Neuromuscul Disord 17:290-6. 2007
    ..2% vs. 12%). The physiological role of myostatin in cardiac muscle appears significantly different than that in skeletal muscle as it does not induce cardiac hypertrophy and does not modulate cardiac fibrosis in mdx mice...
  10. ncbi Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy
    Saman Nazarian
    Department of Medicine, Johns Hopkins University School of Medicine and the Kennedy Krieger Institute, Baltimore, Maryland 21287, USA
    Pacing Clin Electrophysiol 34:171-6. 2011
    ..We sought to characterize the trends and predictors of time-dependent electrocardiographic (ECG) variations in patients with DM1...
  11. ncbi Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice
    Charlotte J Sumner
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Hum Mol Genet 18:3145-52. 2009
    ..Together these results suggest that inhibition of myostatin may not be a promising therapeutic strategy in severe forms of SMA...
  12. ncbi A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis
    Brett M Morrison
    Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
    Exp Neurol 217:258-68. 2009
    ..The improved function of SOD1(G93A) transgenic mice following treatment with ActRIIB.mFc is encouraging for the development of TGF-beta pathway inhibitors to increase muscle strength in patients with ALS...
  13. ncbi Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy
    Daniel P Judge
    Division of Cardiology Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Am J Cardiovasc Drugs 11:287-94. 2011
    ..This article focuses on mechanisms of cardiac dysfunction, as well as potential targets for pharmacologic manipulation to prevent or improve cardiomyopathy in DMD...
  14. ncbi Regeneration versus fibrosis in skeletal muscle
    Adam L Moyer
    Center for Genetic Muscle Disorders, The Kennedy Krieger Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Curr Opin Rheumatol 23:568-73. 2011
    ..This review evaluates recently published literature examining various muscle tissue cells and their modulators that determine whether injured skeletal muscle will fully regenerate or become fibrotic...
  15. ncbi Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics
    Steven A Greenberg
    Department of Neurology, Division of Neuromuscular Disease, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Ann Neurol 71:141-5. 2012
    ..Sequencing in this patient and family members identified the genetic basis of the previously reported 6q23 linked LGMD1D/1E to be due to an intron splice donor site mutation (IVS3+3A>G) of the desmin gene located on chromosome 2q35...
  16. ncbi QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance
    Saman Nazarian
    Department of Medicine Cardiology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Magn Reson Med 64:107-14. 2010
    ..The SNRV of the left ventricle is associated with QRS prolongation, likely due to late depolarization of tissue within islands of patchy fibrosis. The association of SNRV with future clinical events warrants further study...
  17. ncbi Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease
    Javier Bolaños-Meade
    Department of Oncology, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Am J Hematol 78:306-9. 2005
    ..The patient's strength and function improved significantly after discontinuation of hydroxychloroquine...
  18. ncbi Myostatin mutation associated with gross muscle hypertrophy in a child
    Markus Schuelke
    Department of Neuropediatrics, Charit, University Medical Center Berlin, Berlin, Germany
    N Engl J Med 350:2682-8. 2004

Research Grants1

  1. Myostatin in Muscle Growth and Regeneration
    Kathryn Wagner; Fiscal Year: 2005
    ..In addition to the ultimate goal of providing clinical applications for muscle disease, this multidisciplinary approach should provide excellent training for a career integrating clinical myology and molecular neuroscience. ..